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LIST OF ABBREVIATIONS 
 
Addison’s disease: AD 
Autoimmune Hepatitis: AH 
Atrophic Gastritis:  AG 
Autoimmune Thyroiditis: AT 
AutoImmune REgulator gene: AIRE 
Autoimmune Polyendocrinopathy - Candidiasis – Ectodermal - Distrophy: APECED 
Autoantibodies: Abs 
Autoantibodies against Adrenal Cortex: ACA 
 
Autoantibodies against Aromatic-L-Aminoacid decarboxylase: AADCAbs 
Autoantibodies against Glutamic acid decarboxylase: GADA 
Autoantibodies against Islet cells: ICA 
Autoantibodies against Intrinsic Factor: IFA 
Autoantibodies against 17α-hydroxilase: 17α-OHAbs 
Autoantibodies against 21 hydroxilase: 21-OHAbs 
Autoantibodies against melanin producing cells: MPCA 
Autoantibodies against Parietal cells: PCA 
Autoantibodies against Side-chain cleavage enzyme: sccAbs 
Autoantibodies against Steroid-producing cells: StCA 
Autoantibodies against tissue transglutaminase: tTgAbs 
Autoantibodies against Thyroglobulin: TgAbs 
Autoantibodies against Thyroid microsomal: TMAbs 
Autoantibodieas against Tryptophan hydroxylase: TPHAbs 
Autoantibodies against Thyroperoxidase: TPOAbs 
Caspase-recruitment domain: CARD 
Chronic Hypoparathyroidism: CH 
Chronic Mucocutaneous Candidiasis: CMC 
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Ectodermal Dystrophy: ED 
 
Growth Hormone Deficiency: GHD 
Hypergonadotropic Hypogonadism: HH 
Posterior Reversible Encephalopathy Syndrome: PRES 
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ABSTRACT 
 
Background: Autoimmune-Polyendocrinopathy-Candidiasis-Ectodermal-Distrophy (APECED) 
is a recessive disease, caused by mutations in the AutoImmune REgulator (AIRE) gene. Different 
mutations are peculiar of particular populations. In Italy three hot spots areas where APECED 
shows an increased prevalence, have been identified in Sardinia, Apulia and in the Venetian 
region. 
Aim: in this study we analyzed AIRE mutations and genotype-phenotype correlation in  
APECED patients originating from Campania and in their relatives. 
Patients and methods: in six patients affected with APECED clinical findings, genetic analysis 
of AIRE and APECED-related autoantibodies were performed. 
Results: all patients carried at least one mutation on exon 1 or on splice-site flanking exon 1. 
Two siblings carried a complex homozygous mutation [IVS1 + 1G>C; IVS1 + 5delG] on intron  
1; two patients were compound heterozygous for [T16M]+[W78R] (exons 1+2); one patient was 
compound heterozygous for [A21V]+[C322fs] (exons 1+8) and another was homozygous for 
[T16M]+[T16M] on exon 1. Expression of the disease showed wide variability while circulating 
autoantibodies paralleled to phenotype in each patient. Analysis of relatives allowed the 
identification of 8 heterozygotes. None of heterozygous subjects presented major findings of 
APECED. 
Conclusions: mutations localized on exon 1 and the region flanking exon 1 are common in 
APECED patients originating from Campania. Genotype-phenotype correlation failed to reveal a 
relationship between detected mutations and clinical expression. Mutations in heterozygosis in 
AIRE gene are not associated to major findings of APECED. 
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INTRODUCTION 
 
Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal-Distrophy (APECED) is a rare autosomal 
recessive disease (OMIM 240300) which affects many tissues especially endocrine glands (1). The 
diagnosis is primarily based on the presence of two out of the three most common clinical features: 
chronic mucocutaneous candidiasis (CMC), chronic hypoparathyroidism (CH) and Addison’s  
disease (AD). CMC is often the first clinical manifestation to appear before the age of 5 year, 
followed by CH and later by AD. APECED is caused by mutations in the AutoImmune REgulator 
gene (AIRE), which maps to chromosome 21q22.3 (2, 3) and encodes a 55-kDa protein that acts as a 
transcription regulator. Over 60 mutations have by now been localized in the AIRE genes  of 
different APECED patients (4). Even though it occurs through the world, its incidence is higher in 
some genetically isolated populations. The estimated prevalence of APECED is 1:9.000 in Iranian 
Jewes (5), 1:25.000 in Finns (6,7) and 1:14.400 in Sardinians (8). Some different mutations have 
been found to be peculiar of specific areas. R257X is the most common mutation among Finnish and 
other European patients (9-11), 1094-1106del113 (or 967-979del13 bp) is the most common  
mutation in British (12), Irish (13), North America (14,15) and Norwegian patients (16) and the 
Y85C mutation is more frequent among Iranian Jewes (17). 
In Italy three hot spots areas where APECED shows an increased prevalence,  have been identified  
in Sardinia, Apulia and in the Venetian region. Moreover, both in Sardinia and Apulia a peculiar 
mutation of AIRE has been identified: the mutation R139X on exon 3 in Sardinia (18) and the 
mutation W78R on exon 2 in Apulia (19). In Veneto region AIRE gene mutations were different 
from the other Italian regions but similar to that identified in finnish and anglo-saxon patients (20).  
A typical mutation has been recently identified also in Sicily (R203X on exon 5) (20). 
However, the different mutations have not to date been convincingly associated with particular 
disease manifestations (4). 
To the best of our knowledge, only one patient with AIRE mutation was described from Campania 
so far,  having the homozygous mutation c1314-1326 del13/insGT on exon 11 (21). 26 
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Aim of this study was to characterized genotype and phenotype of 6 new APECED patients 
originating from Campania, in the attempt to evaluate their genotype-phenotype correlation. 
Moreover we studied the relatives of these patients in order to evaluate the clinical and biochemical 
effects of heterozygous mutations of the gene. 
 
 
PATIENTS AND METHODS 
 
Patients 
 
Six patients originating from Campania (a region of Southern Italy) affected with APECED (5 F, 1  
M), were investigated. In all of them the onset of the disease was in early childhood; two of them were 
followed up until young adult age. Patients were selected for the presence of signs or symptoms 
suggestive of APECED. Two of the three major criteria of APECED (hypoparathyroidism and chronic 
candidiasis) were present at diagnosis in 5 of them. One patient presented only candidiasis as major 
criteria, but she was enrolled for the association of chronic mucocoutaneous candidiasis with other 
autoimmune diseases (vasculitis, autoimmune thyroiditis, alopecia) in early childhood. The patients 
were originating from 5 unrelated families. They were all originating from Campania region, but the 
areas where they lived or from they had their origins were not close to each other. Consanguinity 
between the parents was identified in only one family with two affected children (third cousins). In the 
6 patients a complete clinical and biochemical evaluation of the major and minor signs and symptoms 
of APECED disease, molecular analysis of AIRE gene and assessment of all APECED-related 
autoantibodies were performed. 
 
Major and minor clinical features of APECED, molecular analysis of AIRE and autoantibodies 
related to APECED syndrome were also evaluated in eight out of the ten parents of the affected 
patients (4M, 4F) (aged 40±10 years), who gave their consent. They all were originating from 
Campania. 
 
 
Analysis of AIRE gene 
 
Genomic DNA was extracted from peripheral blood by Maxwell 16 Systems (Promega  Corporation, 
 
28 Madison WI, USA). All 14 exons of the AIRE gene were amplified with the use of primers located 
20 
21 
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on the respective flanking introns (17) and were analyzed by direct sequencing using the Big Dye 
terminator cycle sequencing Kit and ABI PRISM 3130 automated sequencer (Applied Biosystems, 
Foster City, CA, USA). The analysis included sequencing of the donor/acceptor sites of all the 
introns. 
 
 
Autoantibodies 
 
Autoantibodies against the following antigens were performed by classical indirect 
immunofluorescence technique, complement fixation, ELISA or RIA, as appropriate: Thyroglobulin 
(TgAbs), Thyroid microsomal (TMAbs), Thyroperoxidase (TPOAbs), Parietal cells (PCA), Intrinsic 
factor (IFA), Islet cells (ICA), Glutamic acid decarboxylase (GADA), tissue transglutaminase 
(tTgAbs), Adrenal cortex (ACA), Steroid-producing cells (StCA), melanin producing cells (MPCA). 
Autoantibodies to 21-hydroxilase (21-OHAbs) were tested using RSR’s kit (22). 17α-hydroxilase 
(17α-OHAbs) as well as side-chain cleavage enzyme (sccAbs) autoantibodies were measured using 
specific and sensitive immunoprecipitation assays (IPAs) (23). Autoantibodies to Aromatic-L- 
Aminoacid decarboxylase (AADCAbs) and Tryptophan hydroxylase (TPHAbs) were measured in an 
immunoprecipitation assay using (35)S-labelled full length and fragments of TPH and AADC (24). 
 
 
RESULTS 
 
Clinical presentation and autoantibodies 
 
Clinical characteristics and autoantibodies’ profile of each patient are reported in Table 1. 
 
Patient 1 was born from consanguineous parents (third cousins). He first presented at 1.5 
years of age with a history of transient hypertransaminasemia. At the age of 5 years, he suddenly 
developed an unusually severe phenotype with many signs and symptoms outbreaking over a six 
month period. In fact, the physical examination revealed the presence of vitiligo, nail dystrophy, 
alopecia, oral candidiasis and hepatosplenomegaly. He also suffered from alternating stipsis/diarrhea 
and chronic abdominal pain. Laboratory testing led to diagnosis of autoimmune hepatitis, chronic 
hypoparathyroidism, chronic thyroiditis and Addison’s disease. Endoscopy revealed the presence of 
atrophic gastritis of the body. Six months after the onset of this accelerated phase, the patient 
26 
8 
 
 
 
 
1 
2 
3 1 
4 
5 2 
6 
7 
8 3 
9 
10 4 
11 
12 5 
13 
14 6 
15 
16 7 
17 
18 8 
19 
20 
21 9 
22 
23 10 
24 
25 11 
26 
27 12 
28 
29 13 
30 
31 14 
32 
33 
34 15 
35 
36 16 
37 
38 17 
39 
40 18 
41 
42 19 
43 
44 20 
45 
46 
47 21 
48 
49 22 
50 
51 23 
52 
53 24 
54 
55 25 
56 
57 
58 
59 
60 27 
 
 
 
suddenly developed a severe neurological syndrome with neuroradiological findings suggestive of 
Posterior Reversible Encephalopathy Syndrome (PRES), a life-threatening event never described 
before in APECED patients (Table 1) (25). Screening of autoantibodies revealed the presence of 
TgAbs, TMAbs, TPOAbs, PCA, ACA, 21-OH-Abs, StCA, 17α-OHAbs, AADCAbs, TPHAbs and 
MPCA. sccAbs and GADA were negative (Table 1). 
 
Patient 2 (the younger sister of patient 1), presented at 4 years of age with chronic 
hypoparathyroidism, chronic mucocoutaneous candidiasis and ectodermal dystrophy (Table 1). 
During three years of follow-up, she did not develop any other feature of the disease. None of the 
autoantibodies tested resulted positive (Table 1). 
Patient 3 first presented at the age of 2 years with chronic mucocoutaneous candidiasis, 
chronic abdominal pain and alternating stipsis/diarrhea. At the age of 8 years she was diagnosed as 
having chronic hypoparathyroidism, Addison’s disease, growth hormone deficiency, enamel 
dysplasia and alopecia. At the age of 14 years she developed ungueal dystrophy, chronic thyroiditis 
and hypergonadotropic hypogonadism (Table 1). Autoantibodies’ profile revealed the presence of 
TgAbs, TMAbs, TPOAbs, ICA, ACA, 21-OH-Abs, StCA, 17α-OHAbs, sccAbs, AADCAbs and 
TPHAbs (Table 1). 
Patient 4 first presented at the age of 8 months with vasculitis and splenomegaly. Thereafter, 
at the age of 2 years, she developed chronic mucocutaneous candidiasis and, at the age of 5 years, 
severe alopecia, chronic thyroiditis and recurrent abdominal pain with alternating stipsis/diarrhea 
(Table 1). Autoantibodies’ profile revealed the presence of TgAbs, TMAbs, PCA, ACA, 21-OH-Abs 
StCA, 17α-OHAbs and sccAbs  (Table 1). 
Patient 5 presented with chronic hypoparathyroidism at the age of 2 years. At the age of 3 
years she developed Addison’s disease, chronic oral candidiasis and ungueal dystrophy (Table 1). 
Only 21-OHAbs resulted to be positive. sccAbs, AADCAbs and TPHAbs were negative. During 4 
years of follow-up, she did not show any other signs, symptoms or autoantibody (Table 1). 
Patient 6 first developed chronic hypoparathyroidism, enamel dysplasia and chronic 
mucocoutaneous candidiasis at the age of 6 years.         At the age of 15 years, Addison’s disease and 
26 
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alopecia were also diagnosed (Table 1). Autoantibodies’ profile revealed positivity for ACA, 21- 
OHAbs, and sccAbs (Table 1). 
Noteworthy, autoantibodies paralleled clinical phenotype in each case. Infact, no antibodies were 
detected in patient 2 with only a mild expression of the disease whereas several autoantibodies were 
detected in patients 1 and 3 with a more severe expression of APECED. Globally, the most prevalent 
autoantibodies found were those against 21-Hydroxilase. 
 
 
AIRE mutation analysis 
 
Five different AIRE mutations were detected. Interestingly, all patients carried at least one mutation 
on exon 1 or on splice donor site of intron 1 (Table 1). 
Two siblings carried a complex homozygous mutation in intron 1, consisting of a substitution of 
IVS1 + 1G by C accompanied in cis by a single nucleotide deletion at IVS1 + 5G residue [IVS1 + 
1G>C; IVS1 + 5delG]. Two patients were compound heterozygous for [T16M]+[W78R] on exons 1 
and 2 respectively; one patient was compound heterozygous for [A21V]+[C322fs] on exons 1 and 8, 
respectively and one patient was homozygous for [T16M] +[T16M] on exon 1.  None of the  
mutation described is a novel mutation but the complex variant [IVS1 + 1G>C; IVS1 + 5delG] is 
uncommon. Figure 1 summarizes on both the gene and protein domains mutations detected in this 
study, as well as those previously described. 
 
 
Relatives 
 
Analysis of AIRE gene revealed that all parents were heterozygotes for one of the mutations found in 
the patients, confirming autosomal recessive model of inheritance of APECED. Three of them had a 
mutation on exon 1, two had a complex mutation in intron 1, two had a mutation on exon 2 and one 
had a mutated allele on exon 8. 
Clinical evaluation revealed that none of them was affected by one of the major features of 
APECED. Four of them (3F, 1M) had positive autoantibodies: two against PC, one against TM and 
another against both Tg and PC. 
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DISCUSSION 
 
Recent studies have documented that in four italian regions different AIRE gene mutations have  
been identified. Typical mutations have been identified in Sardinia (R139X on exon 3) (18) , in 
Apulia (W78R on exon 2) (19), in Veneto (R257X on exon 6 and 8) and in Sicily (R203X on exon 5) 
(20). 
In Campania, a region of the Southern Italy, only one case with AIRE mutation has been described 
so far,  carrying an homozygous mutation on exon 11 (c1314-1326 del 13/insGT) (21). 
In our study we have delineated the molecular pathology and the clinical spectrum of 6 more 
probands affected with APECED originating from this region. 
Our results suggest that mutations localized on exon 1 or on the region flanking exon 1, being 
present either in compound heterozygosis or homozygosis, are relatively common in APECED 
patients originating from Campania. 
Exon 1 and the region flanking exon 1, are localized at the aminoterminus of AIRE. This domain  
was long referred to as a homogeneously staining region (HSR) domain but recent evidence suggest 
that this region encompasses a caspase-recruitment domain (CARD) (26). As shown in figure 1, in 
this area most other missense mutations have been located. CARD domains are involved in the 
process of homo- or hetero-dimerization. Aire’s CARD is needed for a correct dimerization of AIRE 
and interactions with other transcriptional control proteins. Thus, missense mutations and also small 
deletions affecting this domain lead to the production of a functionally defective protein due to the 
loss of its homodimerization properties (26). 
None of the mutations detected in our patients is novel. However the complex homozygous mutation 
reported in the two siblings is uncommon. The sequence variant [IVS1 + 1G>C; IVS1 + 5delG] 
consists of two mutations, each likely to affect the splicing of intron 1. The IVS1 + 1G is 100% 
conserved in the major-class introns so that its change into C must render the splice site 
nonfunctional. The IVS1 + 5delG is also likely to have a negative effect because in the major-class 
introns at the IVS+5 position only G,A or T occur. This mutation has never been reported in 
APECED patients from Italy. So far, the IVS1 + 1G>C; IVS1 + 5delG mutation has been described 
in heterozygous state with the R257X in a single individual from Poland (10). 
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Noteworthy, in the six patients described the phenotype was characterized by the presence of several 
unusual (GH deficiency, vasculitis) and life-threatening (PRES, Chronic Hepatitis) complications of 
the disease. In particular, the PRES is a neurological acute syndrome never described before in 
APECED patients (25). GH deficiency and vasculitis also represent very rarely a feature of the 
disease. Moreover, three of our six patients, presented Addison’s disease in early childhood, whereas 
it is commonly reported after the second decade of life. In patients with early development of 
Addison, life-threatening complications (such as autoimmune hepatitis and squamous cell carcinoma 
of the oral mucosa) can occur, and therefore they should be followed more closely. 
Analysis of genotype-phenotype correlation in our subjects failed to reveal a clear relationship, as 
previously reported in other series of patients. All patients had an early onset of the disease, but the 
phenotype and the severity of the disease widely differed even between patients with the same 
mutation of AIRE. In particular the 2 siblings carrying the same complex homozygous mutation 
(patient 1 and 2) showed a wide heterogeneity of clinical expression: one patient developed a severe 
phenotype culminating in a life-threatening event,whereas his sister presented with only a mild 
phenotype. Moreover, their phenotypes were different from the only other patient from Poland 
carrying the same complex mutation. Patient 3 and 4, presenting the same missense mutations 
[T16M]+[W78R], also widely differed in their phenotype: the first patient, in fact, had only a mild 
phenotype characterized by alopecia, ectodermal dystrophy and candidiasis, whereas the second 
patient developed a severe phenotype, with many signs and symptoms, since the first decade of life. 
Also in patients with Addison, the early development of disease was not apparently related to the 
genotype in that the three patients affected carried different mutations of the gene. 
Autoantibodies paralleled clinical phenotype in each case, confirming their role in the pathogenesis 
of the disease. 
The study of the relatives confirmed that the heterozygous state for AIRE mutations is not associated 
to the presence of major signs or symptoms correlated to APECED syndrome, as previously reported 
(20). Accordingly with Cervato et al, in fact, in our heterozygous subjects we only detected latent 
autoimmune diseases as demonstrated by the presence of thyroid or PC autoantibodies in 4 of the 8 
studied  heterozygous.  We  found  only  a  slight  prevalence  in  female  versus  male,  whereas   no 
26 
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differences were detected on the basis of age. However, in all relatives, also those initially negative, 
a longitudinal evaluation of antibodies could be useful in order to identify those subjects that might 
develop clinical or subclinical disease over time. 
In conclusion we described 6 patients characterized by several unusual and life-threating 
complications of APECED. Our analysis failed to reveal a clear genotype-phenotype correlation 
according to previous reports. However, our data demonstrate that APECED in Campania region is 
more frequent than reported so far and that mutations on exon 1and on region flanking exon 1 of 
AIRE gene are common in patients originating  from this region. 
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2 1 Table 1: Clinical manifestations, autoantibodies and AIRE mutations in the 6 APECED patients from Campania 
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 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
Sex M F F F F F 
Age at the onset 
(years) 
1.5 4.0 2.0 0.7 2.0 6.0 
Symptoms/Signs CMC 
CH 
AD 
AT 
AG 
ED 
AH 
Stipsis/diarrhea 
Alopecia 
Vitiligo 
PRES 
CMC 
CH 
ED 
CMC 
CH 
AD 
HH 
AT 
ED 
Enamel dysplasia 
Stipsis/diarrhea 
Alopecia 
GHD 
CMC 
AT 
Stipsis/diarrhea 
Alopecia 
Vasculitis 
CMC 
CH 
AD 
ED 
CMC 
CH 
AD 
Enamel dysplasia 
Alopecia 
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9 
10 
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29 1 
30 2 
31 
32 3 
33 
4
 
 
 
Positive TgAbs  TgAbs TgAbs 21-OHAbs ACA 
Autoantibodies TMAbs TMAbs TMAbs  21-OHAbs 
 TPOAbs TPOAbs PCA  sccAbs 
 PCA ICA ACA   
 ACA ACA 21-OHAbs   
 21OHAbs 21-OHAbs StCA   
 StCA StCA 17-α-OHAbs   
 17-α-OHAbs 17-α-OHAbs sccAbs   
 AADCAbs sccAbs    
 TPHAbs AADCAbs    
 MPCA TPHAbs    
 
Mutation 
Exons 
 
IVS1+1G>C;IVS1+5delG 
 
 
1/1 
 
IVS1+1G>C;IVS1+5delG 
 
 
1/1 
 
T16M/W78R 
 
 
1/2 
 
T16M/W78R 
 
 
1/2 
 
A21V/C322fs 
 
 
1/8 
 
T16M/T16M 
 
 
1/1 
 
AD, Addison’s disease; AG, Atrophic Gastritis; AH, Autoimmune Hepatitis; AT, Autoimmune Thyroiditis; CH, Chronic Hypoparathyroidism; CMC, Chronic 
Mucocutaneous Candidiasis; ED, Ectodermal Dystrophy; HH, Hypergonadotrpoic Hypogonadism; GHD, Growth Hormone Deficiency; PRES, Posterior 
Reversible Encephalopathy Syndrome. 
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40 8 
41 
42 9 
43 
44 
45 
46 
47 
 
against Islet Cells; MPCA, autoantibodies against Melaning Producing Cells; PCA, autoantibodies against Parietal Cells; sccAbs, autoantibodies against side 
chain cleavage enzyme; StCA, autoantibodies against Steroid Producing Cells; TgAbs, autoantibodies against Thyroglobulin; TMAbs, autoantibodies against 
Thyroid Mycrosomal; TPOAbs, autoantibodies against Thyroperoxidase; TPHAbs, autoantibodies against Tryptophan Hydroxilase. 
17 
7 
34  
35 5 AADCAbs, autoantibodies against Aromatic L-Amino Acid Decarboxylase; ACA, autoantibodies against Adrenal Cortex; GADA, autoantibodies against 
36   
37 6 Glutamic Acid Decarboxylase; 17-OHAbs, autoantibodies against 17-Hydroxylase; 21-OHAbs, autoantibodies against 21-Hydroxylase; ICA, autoantibodies 
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